FOLH1 and prostate cancer: This is evident in prostate cancer, for example, with the approval and commercialisation of [177Lu]Lu-PSMA-617 ([177Lu]Lu-vipivotide tetraxetan-Pluvicto®) but is less apparent in neuroendocrine tumours treated with [177Lu]Lu-DOTATATE ([177Lu]Lu-oxodotreotide- Lutathera®), where there are limited approved alternative therapies for patients.